<i>ALK</i> Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature
Activating mutations and fusions of the <i>ALK</i> oncogene have been identified as drivers in a number of malignancies. Crizotinib and subsequent ALK tyrosine kinase inhibitors have improved treatment outcomes for these patients. In this paper, we discuss the case of an adolescent patie...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/7/1842 |
| _version_ | 1827733783042850816 |
|---|---|
| author | Meghan Shekar Gabriela Llaurador Caraballo Jyotinder N. Punia Choladda V. Curry Kevin E. Fisher Michele S. Redell |
| author_facet | Meghan Shekar Gabriela Llaurador Caraballo Jyotinder N. Punia Choladda V. Curry Kevin E. Fisher Michele S. Redell |
| author_sort | Meghan Shekar |
| collection | DOAJ |
| description | Activating mutations and fusions of the <i>ALK</i> oncogene have been identified as drivers in a number of malignancies. Crizotinib and subsequent ALK tyrosine kinase inhibitors have improved treatment outcomes for these patients. In this paper, we discuss the case of an adolescent patient with acute myeloid leukemia, who was identified to have an activating <i>ALK</i> fusion, which is a rare finding and has never been reported in cases of AML without monosomy 7. Crizotinib was added to this patient’s frontline therapy and was well tolerated. In cases of more common gene alterations, existing data supports the use of targeted agents as post-HSCT maintenance therapy; however, crizotinib was not able to be used post-HSCT for this patient due to the inability to obtain insurance coverage. |
| first_indexed | 2024-03-11T01:16:54Z |
| format | Article |
| id | doaj.art-acf507e799af48cab1d1cfaed04d19d0 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T01:16:54Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-acf507e799af48cab1d1cfaed04d19d02023-11-18T18:25:45ZengMDPI AGBiomedicines2227-90592023-06-01117184210.3390/biomedicines11071842<i>ALK</i> Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the LiteratureMeghan Shekar0Gabriela Llaurador Caraballo1Jyotinder N. Punia2Choladda V. Curry3Kevin E. Fisher4Michele S. Redell5Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USADepartment of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USATexas Children’s Hospital, Houston, TX 77030, USATexas Children’s Hospital, Houston, TX 77030, USATexas Children’s Hospital, Houston, TX 77030, USADepartment of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USAActivating mutations and fusions of the <i>ALK</i> oncogene have been identified as drivers in a number of malignancies. Crizotinib and subsequent ALK tyrosine kinase inhibitors have improved treatment outcomes for these patients. In this paper, we discuss the case of an adolescent patient with acute myeloid leukemia, who was identified to have an activating <i>ALK</i> fusion, which is a rare finding and has never been reported in cases of AML without monosomy 7. Crizotinib was added to this patient’s frontline therapy and was well tolerated. In cases of more common gene alterations, existing data supports the use of targeted agents as post-HSCT maintenance therapy; however, crizotinib was not able to be used post-HSCT for this patient due to the inability to obtain insurance coverage.https://www.mdpi.com/2227-9059/11/7/1842acute myeloid leukemiatargeted therapycytogeneticsALK |
| spellingShingle | Meghan Shekar Gabriela Llaurador Caraballo Jyotinder N. Punia Choladda V. Curry Kevin E. Fisher Michele S. Redell <i>ALK</i> Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature Biomedicines acute myeloid leukemia targeted therapy cytogenetics ALK |
| title | <i>ALK</i> Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature |
| title_full | <i>ALK</i> Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature |
| title_fullStr | <i>ALK</i> Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature |
| title_full_unstemmed | <i>ALK</i> Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature |
| title_short | <i>ALK</i> Fusion in an Adolescent with Acute Myeloid Leukemia: A Case Report and Review of the Literature |
| title_sort | i alk i fusion in an adolescent with acute myeloid leukemia a case report and review of the literature |
| topic | acute myeloid leukemia targeted therapy cytogenetics ALK |
| url | https://www.mdpi.com/2227-9059/11/7/1842 |
| work_keys_str_mv | AT meghanshekar ialkifusioninanadolescentwithacutemyeloidleukemiaacasereportandreviewoftheliterature AT gabrielallauradorcaraballo ialkifusioninanadolescentwithacutemyeloidleukemiaacasereportandreviewoftheliterature AT jyotindernpunia ialkifusioninanadolescentwithacutemyeloidleukemiaacasereportandreviewoftheliterature AT choladdavcurry ialkifusioninanadolescentwithacutemyeloidleukemiaacasereportandreviewoftheliterature AT kevinefisher ialkifusioninanadolescentwithacutemyeloidleukemiaacasereportandreviewoftheliterature AT michelesredell ialkifusioninanadolescentwithacutemyeloidleukemiaacasereportandreviewoftheliterature |